Showing 156 results

Filters Content type: News, Editors' picks, About HIV Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

Long-Acting PrEP in Europe's Fight Against HIV

Editor's pick
Medscape (requires free registration)
1 December 2023

Pharma Pricing Secrecy Runs Amok

Editor's pick
Health GAP (Global Access Project)
20 August 2023